Novartis faces criticism over Zolgensma ‘health lottery’

Novartis faces criticism over Zolgensma ‘health lottery’

Source: 
PM Live
snippet: 

Novartis has responded to criticism over its managed access program for spinal muscular atrophy (SMA) gene therapy Zolgensma, with patient groups accusing the company of exercising an unfair ‘health lottery’.